BFM
ADMA icon

Boothbay Fund Management’s ADMA Biologics ADMA Stock Holding History

Boothbay Fund Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$523K Hold
62,500
– – 0.01% 1462
2026
Q1 		$563K Buy
+62,500
New +$986K 0.01% 1278

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Boothbay Fund Management's ADMA Position: Q2 2026 in Review

Boothbay Fund Management increased its ADMA Biologics (ADMA) stake by 19% in Q2 2026, buying an estimated $1.68M and bringing the position to 1,176,682 shares worth $9.85M. The position accounts for 0.13% of the portfolio, ranked #169.

Boothbay Fund Management first reported a position in ADMA in Q1 2020 and has held it in 22 quarters since. The position peaked at $20.5M in Q2 2022. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Boothbay Fund Management held 1,176,682 shares of ADMA Biologics worth $9.85M as of Q2 2026.
  • Boothbay Fund Management bought 184,799 ADMA Biologics shares in Q2 2026, an estimated $1.68M.
  • ADMA Biologics made up 0.13% of Boothbay Fund Management's portfolio in Q2 2026, its #169 holding.
  • Boothbay Fund Management first reported a position in ADMA Biologics in Q1 2020 and has held it in 22 quarters since.
  • Boothbay Fund Management's ADMA Biologics position peaked at $20.5M in Q2 2022.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.